Plasmagen Biosciences introduces CSL’s Haemocomplettan P in India

New Delhi: Plasmagen Biosciences Private Ltd., specialising in Plasma Protein and Speciality Care Therapy, has announced the introduction of Haemocomplettan P (Human Fibrinogen Concenrate), manufactured by CSL Behring, a business unit of CSL, in the Indian market through an exclusive distributorship agreement.

Haemocomplettan P is approved for therapy and prophylaxis of haemorrhagic diatheses in congenital afibrinogenaemia and acquired hypofibrinogenaemia, the company said.

With approximately 1,50,000 cardiac surgeries and around 1,800 liver transplants being performed in India every year, there is a huge need for such therapies in the country. Approximately 1 out of every 2 cardiac surgery patients requires blood transfusion to manage haemorrhage, and over 25 percent of blood transfusions in hospitals are for liver transplant recipients and Haemocomplettan P could be used specially for massive haemorrhagic cases.

“The Collaboration of Plasmagen and CSL Behring will not only further open new avenues in different specialties which includes Cardiac, Liver Transplant, Gastroenterology and Pediatrics but also ensure access to quality products with global safety standards in the biopharmaceutical space. We are also committed towards providing holistic solutions in therapy shaping, disease awareness and patient education”, said  Vinod Nahar, Managing Director, Plasmagen Biosciences, the statement said.